clinical trial · NCT04968106
Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)
Institut Bergonié·phase2·active not recruiting·n = 66
Resectable SarcomaDoxorubicinIfosfamideINCMGA00012
brief summary
Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of retifanlimab (INCMGA00012) in association with neoadjuvant chemotherapy
started
Dec 7, 2022
primary completion
Aug 6, 2025
completion
Apr 1, 2028
last updated
Apr 21, 2026
detailed description
This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (1:1) phase II trial. Patients will be randomized between arm A (neodjuvant chemotherapy by doxorubicin + ifosfamide) and arm B (neodjuvant chemotherapy by doxorubicin + ifosfamide and retifanlimab) with one patient randomized in arm A for one patient randomized in arm B.
official title
Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Retifanlimab (INCMGA00012) in Patients With Selected Sarcomas
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol